NOTABLE LABS, LTD.

Analyst Reco. Notable Labs, Ltd.

Equities

NTBL

IL0012002452

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
0.914 ^USD	-0.65%		-6.82%	-51.64%

Apr. 15	Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating	MT
Apr. 15	Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating	Apr. 15	MT
Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating	Apr. 15	MT
JMP Securities Cuts Notable Labs' Price Target to $9 From $13, Keeps Market Outperform Rating	Dec. 19	MT
Chardan Research Downgrades Vascular Biogenics to Neutral From Buy After OVAL Trial Fails to Meeting Enpoints	22-07-20	MT
Oppenheimer Downgrades Vascular Biogenics to Perform From Outperform, Removes $5.50 Price Target	22-07-20	MT
HC Wainwright Downgrades Vascular Biogenics to Neutral From Buy	22-07-20	MT
Chardan Capital Initiates Vascular Biogenics at Buy with $5 Price Target	22-04-28	MT
VASCULAR BIOGENICS : Chardan Suspends Coverage on Vascular Biogenics at Buy Rating With $5 Price Target	21-08-02	MT
VASCULAR BIOGENICS : Roth Capital Adjusts Vascular Biogenics PT to $7 From $5, Maintains Buy Rating	21-06-03	MT
VASCULAR BIOGENICS : Guggenheim Starts Vascular Biogenics at Buy With $7 Price Target	21-05-18	MT
VASCULAR BIOGENICS : HC Wainwright Adjusts Vascular Biogenics' Price Target to $4 from $3, Keeps Buy Rating	21-01-28	MT
VASCULAR BIOGENICS : Oppenheimer Adjusts Vascular Biogenics PT to $5 From $2.50, Maintains Outperform Rating	21-01-13	MT
VBL Presents Positive Interim Data from the OVAL Phase 3 Pivotal Study in Ovarian Cancer At the ASCO 20 Annual Meeting, Showing 58% or Higher Objective Response Rate	20-06-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer